Previous 10 | Next 10 |
During the semi-annual review, Clovis Oncology (CLVS -1.1%), 22nd Century Group (XXII -1.2%), Verastem (VSTM +8.7%), Omeros (OMER -0.7%), Therapeutics MD (TXMD -3.2%), CEL-SCI (CVM +2.1%), ZIOPHARM Oncology (ZIOP -1.9%), Karyopharm Therapeutics (KPTI +1.1%), Esperion Therapeutics (E...
Image source: The Motley Fool. TherapeuticsMD, Inc. (NASDAQ: TXMD) Q3 2021 Earnings Call Nov 11, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: TherapeuticsMD, Inc. (TXMD) Q3 2021 Earnings Call Transcript
The following slide deck was published by TherapeuticsMD, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: TherapeuticsMD, Inc. 2021 Q3 - Results - Earnings Call Presentation
TherapeuticsMD, Inc. (TXMD) Q3 Earnings Conference Call November 11, 2021, 08:30 AM ET Company Participants Lisa Wilson – Investor Relations Rob Finizio – Chief Executive Officer Hugh O’Dowd – President James D'Arecca – Chief Financial Officer Mark Glickman ...
TherapeuticsMD (NASDAQ:TXMD) has announced a new cost savings initiative designed to save at least $40M beginning in 2022. The company also says it will save $20M annually due to the divestiture of vitaCare. In Q3 2021, TherapeuticsMD's net loss widened ~45% to $47.4M (-$0.11 per basic and di...
Therapeutics MD (NASDAQ:TXMD): Q3 GAAP EPS of -$0.11 misses by $0.01. Revenue of $25.4M (+31.3% Y/Y) misses by $0.47M. Shares +3.35% PM. Press Release As of September 30, 2021, the Company’s cash on hand totaled $104.8M, compared with $80.5M as of December 31, 2020 For further detail...
- Quarterly total net product revenue of $24.5 million, an increase of 41.1% over Q3 2020 - - ANNOVERA ® TRx of 8,351, an increase of 62.7% over Q3 2020 - - Cost savings initiative to reduce SG&A by $40 million in 2022; anticipated additional savings of approximatel...
- Mr. O’Dowd to succeed Robert G. Finizio, effective on or before December 31, 2021 - - Mr. Finizio appointed Vice Chair of the Board - TherapeuticsMD, Inc. (NASDAQ: TXMD) (TXMD or the Company), an innovative, leading women’s healthcare company, today announced...
Therapeutics MD (NASDAQ:TXMD) is scheduled to announce Q3 earnings results on Thursday, November 11th, before market open. The consensus EPS Estimate is -$0.10 (+16.7% Y/Y) and the consensus Revenue Estimate is $25.87M (+33.8% Y/Y). Over the last 1 year, TXMD has beaten EPS estimates 25% of t...
AEG, OTCQX:ALEAF, AMTX, AYRO, AZUL, BAM, BGRY, CAE, CELH, OTCQX:CRLBF, DCBO, OTCQX:EDVMF, GRWG, HUT, IMV, OTCPK:MKGAF, NICE, NVVE, OGN, PSFE, QSI, RSLS, RWLK, SBH, SPCB, SPH, STNG, STXS, THRY, TMDI, TPR, TXMD, UTZ, VNRX, WB, WIX, WWR, XNET, YETI For Seeking Alpha's full earnings season calend...
News, Short Squeeze, Breakout and More Instantly...
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...